NYSE:CI
NYSE:CIHealthcare

Cigna (CI) Valuation Check After Legal Probe and Rising Medical Cost Ratio Pressure

After Cigna Group (CI) reported third quarter results showing a higher Healthcare Medical Cost Ratio that pointed to slimmer future margins, the stock dropped about 17%, drawing legal scrutiny from Levi and Korsinsky. See our latest analysis for Cigna Group. That sharp post earnings sell off stands in contrast to Cigna Group's relatively steady share price performance this year, with a modest year to date share price return and a muted one year total shareholder return signaling fading...
NYSE:CARR
NYSE:CARRBuilding

Carrier Global (CARR): Assessing Valuation After a 22% Share Price Slide

Carrier Global (CARR) has quietly slipped about 22% over the past year even as revenue and net income continue to grow, creating an interesting setup for investors watching climate and energy solutions demand. See our latest analysis for Carrier Global. That slide contrasts with a solid three year total shareholder return of about 36%, suggesting the recent weakness in the share price, now around $53.50, reflects a reset in sentiment rather than a broken long term story. If Carrier’s mix of...
NasdaqGS:TROW
NasdaqGS:TROWCapital Markets

Goldman Sachs Alliance Could Be A Game Changer For T. Rowe Price Group (TROW)

Goldman Sachs Asset Management and T. Rowe Price recently launched their first co-branded model portfolios under a September alliance, offering ETF, tax-aware hybrid, and future high-net-worth solutions to advisors via GeoWealth’s UMA platform. This collaboration combines two large active managers’ fund line-ups and nationwide wholesaling resources, potentially deepening T. Rowe Price’s reach with RIAs and wealth managers serving affluent clients. Next, we’ll examine how this co-branded...
NYSE:V
NYSE:VDiversified Financial

Did Visa’s USDC and AI Push Plus Escrow Move Just Shift Visa’s (V) Investment Narrative?

In recent days, Visa Inc. has authorized a US$500 million deposit into its U.S. litigation escrow account while highlighting solid holiday spending trends and rolling out USDC stablecoin settlement and AI-powered commerce initiatives across its network. Together, these moves show Visa simultaneously tightening its approach to legal risk, reinforcing consumer spending insights, and pushing into next-generation payment infrastructure from stablecoins to agentic AI checkout. We’ll now examine...
NYSE:GEV
NYSE:GEVElectrical

Has GE Vernova’s 97% 2025 Surge Already Reflected Its Energy Transition Potential?

Wondering if GE Vernova is still worth chasing after its big run up, or whether the market has already priced in the story. The stock has surged recently, up 8.7% over the last week, 15.0% over the past month, and 96.9% year to date, while gaining 92.5% over the last year. Those moves have come as investors focus on GE Vernova's role in the energy transition and its positioning across grid, power, and renewables, which are all seeing renewed policy and capital support. At the same time, the...
NasdaqGS:CROX
NasdaqGS:CROXLuxury

Does Crocs’ 2025 Valuation Reflect Its Cash Flows After Recent Share Price Rebound?

Wondering if Crocs at around $90 a share is still a quirky fashion fad or a genuine value opportunity? Let us break down what the market might be missing. The stock has bounced 1.3% over the last week and 9.1% over the past month, yet it is still down 17.6% year to date and 19.8% over the last year. This mix hints at shifting sentiment and potential mispricing. Recent headlines have focused on Crocs expanding its classic clogs and HeyDude brand presence, alongside new collaborations that...
NasdaqGS:KLAC
NasdaqGS:KLACSemiconductor

Is It Too Late To Consider KLA After Its 100% Rally In 2025?

How Has KLA Performed Recently? With KLA up 9.0% over the last week, 12.3% over the last month, and an eye catching 100.6% year to date, it is fair to ask whether the market has simply rerated the stock or is pricing in a much stronger long term outlook. Those moves sit on top of a 98.0% gain over the last year and a remarkable 418.0% return over five years, which puts KLA firmly in the market outperformer camp. This kind of sustained performance often signals a mix of structural tailwinds in...
NasdaqGS:OTEX
NasdaqGS:OTEXSoftware

Open Text (NasdaqGS:OTEX): Is The Market Underestimating Its Valuation After Recent Momentum Cooldown?

Open Text (OTEX) has drifted slightly over the past month, but the longer term picture is more interesting. The stock is up about 24% over the past year despite a weaker past 3 months. See our latest analysis for Open Text. That mix of a solid year to date share price return, while the last quarter has slipped back, suggests momentum has cooled a bit as investors reassess growth and integration risks, even though the one year total shareholder return remains comfortably positive. If Open Text...
NasdaqGS:FSLR
NasdaqGS:FSLRSemiconductor

Assessing First Solar (FSLR) Valuation After 52-Week High Volatility and Alphabet–Intersect Power Deal

First Solar (FSLR) just delivered a wild session, sliding about 6% after touching a fresh 52 week high as investors debated stretched valuations while digesting Alphabet’s planned acquisition of key customer Intersect Power. See our latest analysis for First Solar. Zooming out, the $272.21 share price sits on top of a powerful run, with a roughly 46 percent year to date share price return and an even stronger multi year total shareholder return that signals momentum is still building rather...
NYSE:IONQ
NYSE:IONQTech

IonQ (IONQ) Valuation Check After Recent Pullback and Three-Year Surge in Shareholder Returns

IonQ (IONQ) has been on traders’ radar after a choppy few months, with the stock sliding nearly 28% over the past 3 months but still up about 16% year to date. See our latest analysis for IonQ. At around $49.82, IonQ’s recent 7 day share price return of 8.66% and modest year to date gain contrast with a still impressive three year total shareholder return of nearly 1,500%. This hints that momentum is cooling, but the long term growth story remains very much alive. If IonQ’s swings have you...
NYSE:ZTS
NYSE:ZTSPharmaceuticals

Does Zoetis’ Recent 22.8% Share Price Slide Signal a Long Term Opportunity?

If you have been wondering whether Zoetis is starting to look like a bargain or just a value trap in the making, you are not alone. This article will unpack what the current price is really telling us. Despite being down about 22.8% over the last year and year to date, Zoetis has shown a modest bounce recently, with the share price up 2.7% over the past week and 2.1% over the past month, hinting that sentiment might be stabilizing. Investors have been reacting to a mix of headlines around...
NYSE:RCL
NYSE:RCLHospitality

Does Royal Caribbean Still Offer Value After a 521% Three Year Surge?

Wondering if Royal Caribbean Cruises is still a smart buy after its massive rebound, or if you are late to the party? This breakdown will help you separate real value from the sea of hype. The stock has sailed to $294.12, climbing 3.2% over the last week, 15.1% over the last month, 28.4% year to date, and an eye catching 521.4% over three years. Those gains have come as investors have leaned into the cruise recovery story, with Royal Caribbean benefiting from surging demand for leisure...
NYSE:MCO
NYSE:MCOCapital Markets

Does Moody’s HQ Move And Record Quarter Redefine The Bull Case For MCO?

Earlier this week, Moody’s Corporation said it will relocate its global headquarters to 200 Liberty Street at Brookfield Place in Lower Manhattan by 2027, as part of a broader global office enhancement program spanning cities such as London, Sydney, Tokyo, Milan and Washington, D.C. This move, alongside a recent quarter of record US$2.01 billion revenue, 11% year-over-year growth and higher adjusted margins, underlines how Moody’s is pairing physical workplace upgrades with strong operating...
NasdaqGS:KMB
NasdaqGS:KMBHousehold Products

Did Forecast Q4 Profit Dip and Earnings Beat Streak Just Shift Kimberly-Clark's (KMB) Investment Narrative?

Kimberly-Clark Corporation has announced it will release its fiscal fourth-quarter earnings before the market opens on January 27, 2026, with analysts forecasting a small year-over-year profit decline. Despite this expected dip, the company has matched or beaten Wall Street earnings estimates in each of the last four quarters, heightening interest in whether that pattern can continue. With analysts projecting a slight earnings pullback, we’ll now examine how this upcoming report could...
NasdaqGS:BTSG
NasdaqGS:BTSGHealthcare

BrightSpring Health Services (BTSG): Assessing Valuation After a Strong 90-Day Share Price Rally

BrightSpring Health Services (BTSG) has been quietly rewarding patient shareholders, with the stock climbing about 41% over the past 3 months and more than doubling year to date. This performance is prompting closer attention to what is driving the move. See our latest analysis for BrightSpring Health Services. With the share price now at $37.73 and a 90 day share price return of about 41%, the momentum behind BrightSpring looks firmly upward. This reinforces a strong year to date share price...
NYSE:BSX
NYSE:BSXMedical Equipment

Does Boston Scientific’s Strong Run Match Its Current Valuation in 2025?

If you have been wondering whether Boston Scientific is still a smart buy after its big run in recent years, this breakdown will help you decide if the current price actually makes sense. The stock is up 110.0% over 3 years and 170.4% over 5 years, while more recently it is up 1.7% in the last week, down 1.9% over 30 days, and sitting on a 7.6% gain year to date plus a 5.6% return over the last year. Behind these moves, investors have been digesting continued momentum in Boston Scientific's...
NYSE:BAH
NYSE:BAHProfessional Services

Assessing Booz Allen Hamilton’s Valuation After Its Addition to the S&P 1000 Index

Booz Allen Hamilton Holding (BAH) just secured a spot in the S&P 1000, a move that can quietly change the stock’s demand profile as index trackers and small cap managers adjust their allocations. See our latest analysis for Booz Allen Hamilton Holding. The S&P 1000 inclusion comes after a choppy stretch, with the share price at $85.15 and a roughly 5 percent 1 month share price return, but a weaker year to date share price return alongside a negative 1 year total shareholder return. This...
NasdaqGS:SEIC
NasdaqGS:SEICCapital Markets

SEI Investments (SEIC): Assessing Valuation as Founder Alfred West Prepares to Hand Over the Chairmanship

SEI Investments (SEIC) just hit a major milestone, as founder Alfred P. West, Jr. prepares to step down as Executive Chairman and director on January 1, 2026, handing the chair role to Carl A. Guarino. See our latest analysis for SEI Investments. The leadership handover comes as SEI Investments trades at $85.37, with a 30 day share price return of 7.60 percent pointing to building momentum, while a three year total shareholder return near 53 percent underlines its longer term wealth...
NasdaqGS:FISV
NasdaqGS:FISVDiversified Financial

Fiserv (FISV) Valuation Check After New AI-Powered Visa Partnership in Agentic Commerce and Trusted Agent Protocol

Fiserv (FISV) just unveiled a high profile collaboration with Visa to roll out AI driven agentic commerce and the Trusted Agent Protocol across its merchant network, signaling a meaningful upgrade to its payment security capabilities. See our latest analysis for Fiserv. Despite this ambitious Visa collaboration and other moves like new co brand processing mandates and leadership changes in investor relations, Fiserv’s momentum has been mixed, with a sharp year to date share price return...
NYSE:WM
NYSE:WMCommercial Services

Evaluating Waste Management (WM)’s Valuation After Its 2026 Dividend Hike and New $3 Billion Buyback Program

Waste Management (WM) just doubled down on being a shareholder friendly utility-like stock by rolling out a 14.5% dividend hike for 2026 alongside a fresh $3 billion buyback authorization. See our latest analysis for Waste Management. The shareholder friendly playbook appears to be resonating, with the stock’s recent 1 month share price return of 4.5 percent building on a solid 10.4 percent year to date share price gain and a 5 year total shareholder return above 100 percent. This suggests...
OTCPK:SWRD
OTCPK:SWRDDiversified Financial

Stewards (SWRD) Valuation Check After Governance Shake‑Up and Planned Nasdaq Uplisting

Stewards (OTCPK:SWRD) just gave investors a fresh governance catalyst by appointing veteran finance executive John Bode as board member and audit committee chair as the company gears up for a planned Nasdaq uplisting. See our latest analysis for Stewards. The governance upgrade is landing just as momentum in Stewards' shares has accelerated, with a 1 day share price return near 20 percent, a roughly 46 percent 1 month share price return, and a powerful year to date share price return above...
NasdaqGS:LULU
NasdaqGS:LULULuxury

Lululemon (LULU): Reassessing Valuation After a 24% One-Month Share Price Rebound

lululemon athletica (LULU) has been on a sharp rebound recently, with the stock climbing about 24% over the past month and 22% in the past 3 months after a tough year. See our latest analysis for lululemon athletica. That sharp rebound stands in contrast to a tough stretch, with the share price still well below its early year levels despite the recent 1 month share price return of roughly 24 percent. This suggests sentiment may be stabilizing rather than fully turning. If lululemon’s move has...
NasdaqGS:CCOI
NasdaqGS:CCOITelecom

A look at Cogent Communications (CCOI) valuation after dividend slash, revenue decline and fresh legal scrutiny

Dividend shock and legal scrutiny reshape the picture for Cogent Communications Holdings Cogent Communications Holdings (CCOI) just slashed its dividend by 98% and reported service revenue down about 6% year over year. This combination sent the stock tumbling and triggered a fresh securities law investigation. See our latest analysis for Cogent Communications Holdings. The sudden 98 percent dividend cut and revenue slip come on top of a brutal stretch, with Cogent’s share price down about 71...
NasdaqGS:AGIO
NasdaqGS:AGIOBiotechs

Why Agios Pharmaceuticals (AGIO) Is Up 14.6% After First-in-Class Thalassemia Drug AQVESME Wins FDA Approval

Agios Pharmaceuticals has now received U.S. FDA approval for AQVESME (mitapivat) to treat anemia in adults with alpha- or beta-thalassemia, covering both non-transfusion-dependent and transfusion-dependent patients, with U.S. availability expected after implementation of a required REMS program in late January 2026. The approval, grounded in positive ENERGIZE and ENERGIZE-T Phase 3 data showing reduced transfusion burden and better quality-of-life measures, transforms AQVESME into a new...